Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

被引：0

作者：

Alessi, Joao Victor Machado

Ricciuti, Biagio

Aguilar, Elizabeth Jimenez

Hong, Fangxin

Wei, Zihan

Nishino, Mizuki

Plodkowski, Andrew J.

Sawan, Peter

Luo, Jia

Rizvi, Hira

Carter, Brett W.

Heymach, John

Altan, Mehmet

Hellmann, Matthew David

Awad, Mark M.

机构：

[1] Hosp Sirio Libanes, Sao Paulo, Brazil

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Univ, Biostat Core, Boston, MA 02115 USA

[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[9] MD Anderson Canc Ctr, Houston, TX USA

[10] Massachusetts Gen Hosp, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9568

引用

页数：2

共 50 条

[41] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
Isla, Dolores
Lopez-Brea, Marta
Espinosa, Maria
Arrabal, Natalia
Perez-Parente, Diego
Carcedo, David
Bernabe-Caro, Reyes
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
[42] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
Dolores Isla
Marta Lopez-Brea
María Espinosa
Natalia Arrabal
Diego Pérez-Parente
David Carcedo
Reyes Bernabé-Caro
Cost Effectiveness and Resource Allocation, 21
[43] Pembrolizumab for the first-line treatment of non-small cell lung cancer
Ninomiya, Kiichiro
Hotta, Katsuyuki
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
[44] PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Majem, Margarita
Cobo, Manuel
Isla, Dolores
Marquez-Medina, Diego
Rodriguez-Abreu, Delvys
Casal-Rubio, Joaquin
Moran-Bueno, Teresa
Bernabe-Caro, Reyes
Perez-Parente, Diego
Ruiz-Gracia, Pedro
Arroyo, Marta Marina
Paz-Ares, Luis
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
[45] Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
Jimenez Galan, Rocio
Prado-Mel, Elena
Antonia Perez-Moreno, Maria
Caballano-Infantes, Estefania
Flores Moreno, Sandra
BIOLOGY-BASEL, 2021, 10 (09):
[46] First-line treatment for advanced non-small-cell lung cancer
Laskin, Janessa J.
Sandler, Alan B.
ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
[47] First-line immunotherapy in advanced non-small-cell lung cancer
Noronha, Vanita
Mehta, Prashant
Malik, Prabhat Singh
Patel, Amol
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
[48] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab
Yamaguchi, Ou
Kaira, Kyoichi
Shinomiya, Shun
Mouri, Atsuto
Hashimoto, Kosuke
Shiono, Ayako
Miura, Yu
Akagami, Tomoe
Imai, Hisao
Kobayashi, Kunihiko
Kagamu, Hiroshi
THORACIC CANCER, 2021, 12 (03) : 304 - 313
[49] Erlotinib in the first-line treatment of non-small-cell lung cancer
D'Arcangelo, Manolo
Cappuzzo, Federico
EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
[50] Paclitaxel poliglumex/carboplatin is similar to paclitaxel/carboplatin as first-line treatment in elderly patients with advanced non-small-cell lung cancer and a poor performance status
不详
CLINICAL LUNG CANCER, 2005, 7 (01) : 20 - 22

← 1 2 3 4 5 →